Citwal Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.20 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2019
About Citwal Pharmaceuticals
Citwal Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 March 2018 (Six years and 11 months 6 days old ). Its registered office is in Kollam, Kerala, India.
The Corporate was formerly known as Ocher Pharmaceuticals Private Limited. The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Vasumathi Rijees, Navas Rehuman, and Pradeep Muraleedharannair serve as directors at the Company.
Company Details
- Location
Kollam, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999KL2018PTC052557
- Company No.
052557
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Mar 2018
- Date of AGM
31 Aug 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Citwal Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vasumathi Rijees  | Director | 21-Mar-2018 | Current |
| Navas Rehuman | Director | 21-Mar-2018 | Current |
| Pradeep Muraleedharannair | Director | 21-Mar-2018 | Current |
Financial Performance of Citwal Pharmaceuticals.
Enhance accessibility to Citwal Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Citwal Pharmaceuticals?
Unlock access to Citwal Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Naajco Contracting Private LimitedNavas Rehuman is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Citwal Pharmaceuticals?
Unlock and access historical data on people associated with Citwal Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Citwal Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Citwal Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.